“…Even after complete resection, a high risk of recurrence of ACC remains. Age < 4 years, tumor size < 10 cm [14], virilization alone [15], tumor volume < 200 cm 3 [16, 17], tumor weight and stage [18], metastatic disease [14], and quality of surgery [14, 19] have been suggested as important prognostic markers. Despite multimodality approaches including mitotane [an adrenolytic drug: (o,p’-DDD: 1,1-dichloro-2-o-chlorophenyl)-2-(p-chlorophenyl) ethane], chemotherapy with cisplatin, etoposide and doxorubicin (CED), and radiotherapy, prognosis of pediatric ACC remains poor with an estimated 5-year survival rate ranging from 30 to 90% [2, 4, 15, 18, 20].…”